Tag - FBIO

Markets

Avenue Therapeutics Reaches Final Agreement with FDA for the Phase 3 Safety Study for IV Tramadol

Fortress Biotech (NASDAQ:FBIO) partner company, Avenue Therapeutics (NASDAQ:ATXI) announced that it reached a final agreement with the FDA on the Phase 3 safety study protocol and statistical analysis approach...

January 4, 2024

Markets

Dawson James starts Fortress Biotech at buy; PT $19

Dawson James Securities launched coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and price target of $19. The stock closed at $6.51 on Aug. 23. “Creating a launch pad for biotechnology assets, Fortress...

August 26, 2019

Tag - FBIO

Avenue Therapeutics Reaches Final Agreement with FDA for the Phase 3 Safety Study for IV Tramadol

Dawson James starts Fortress Biotech at buy; PT $19

General

More